Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GPR55 in the tumor microenvironment of pancreatic cancer controls tumorigenesis

ABSTRACT: GPR55 in the tumor microenvironment of pancreatic cancer controls tumorigenesis

PROVIDER: PRJNA1179863 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31157309_1.fastq.gz	Fastqsanger.gz
	SRR31157309_2.fastq.gz	Fastqsanger.gz
	SRR31157310_1.fastq.gz	Fastqsanger.gz
	SRR31157310_2.fastq.gz	Fastqsanger.gz
	SRR31157311_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

GPR55 in the tumor microenvironment of pancreatic cancer controls tumorigenesis

Project description:The G protein-coupled receptor 55 (GPR55) is part of an expanded endocannabinoid system (ECS), and plays a pro-tumorigenic role in different cancer models, including pancreatic cancer. Next to cancer cells, various cells of the immune tumor microenvironment (TME) express receptors of the ECS that critically determine tumor growth. The role of GPR55 in cancer cells has been widely described, but its role in the immune TME is not well understood. We, therefore, intended to uncover the role of GPR55 in tumor immunity in a model of pancreatic ductal adenocarcinoma (PDAC). To this end, a KPCY tumor cell line from murine PDAC, or GPR55-overexpressing KPCY cells (KPCY55) were subcutaneously injected into wildtype (WT) and GPR55 knockout (KO) mice, and immune cell populations were evaluated by flow cytometry. Deficiency of GPR55 in the TME led to reduced tumor weight and volume, and altered the immune cell composition of tumors, favoring an anti-tumorigenic environment by increasing the number of CD3+ T cells, particularly CD8+ T cells, and the expression of PD-L1 on macrophages. RNA-seq pathway analysis revealed higher T cell activity in KPCY55 tumors of GPR55 KO vs. WT mice. In addition, tumors from GPR55 KO mice displayed increased levels of T cell chemokines Cxcl9 and Cxcl10. Migration of T cells from GPR55 KO mice towards CXCL9 was increased in comparison to T cells from WT mice, suggesting that a CXCR3/CXCL9 axis was involved in T cell influx into tumors of GPR55 KO mice. Notably, anti-PD-1 immunotherapy increased tumor burden in WT mice, while this effect was absent in the GPR55 KO mice. Our study indicates that GPR55 in TME cells may drive tumor growth by suppressing T cell functions, such as migration, in a model of PDAC, making it an interesting target for immunotherapies.

2025-01-20 | GSE280636 | GEO

Pancreatic Tumor Microenvironment Maintains Tumor Growth through Nucleosides Secretion

Project description:Pancreatic Tumor Microenvironment Maintains Tumor Growth through Nucleosides Secretion

| PRJNA770663 | ENA

Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells

Project description:Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells

| PRJNA422050 | ENA

GPR55 in the tumor microenvironment of pancreatic cancer controls tumorigenesis.

Project description: Not available

| S-EPMC11779727 | biostudies-literature

LY6D Identifies Persistent Tumor-Initiating Cells Driving Pancreatic Tumorigenesis

Project description:LY6D Identifies Persistent Tumor-Initiating Cells Driving Pancreatic Tumorigenesis

| PRJNA1379351 | ENA

Pancreatic Tumor Microenvironment Maintains Tumor Growth through Nucleosides Secretion

Project description:Cancer-associated fibroblasts (CAFs) are one of the most prominent and active components in the pancreatic tumor microenvironment. Our data show that CAFs are critical for PDAC survival upon glutamine deprivation. Specifically, we uncovered a role for nucleosides, which are secreted by CAFs through autophagy in an NUFIP1-depenent manner, increased glucose utilization and promoted growth of PDAC. Moreover, we demonstrate that CAF-derived nucleosides induced glucose consumption under glutamine-deprived conditions and displayed a dependence on MYC. Using an orthotopic mouse model of PDAC, we found that inhibiting nucleoside secretion by targeting NUFIP1 in the stroma reduced tumor weight. This finding highlights a previously unappreciated metabolic network within pancreatic tumors in which diverse nutrients are used to promote growth in an austere tumor microenvironment.

2021-10-19 | GSE185750 | GEO

TMEM16F Phospholipid Scramblase Regulates Tumorigenesis by Modulating the Tumor Immune Microenvironment

Project description:TMEM16F Phospholipid Scramblase Regulates Tumorigenesis by Modulating the Tumor Immune Microenvironment

| PRJNA1244404 | ENA

Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors

Project description:<p>Nutrient-deprived conditions in the tumor microenvironment (TME) restrain cancer cell viability due to increased free radicals and reduced energy production. In pancreatic cancer cells, a cytosolic metabolic enzyme, wild-type isocitrate dehydrogenase 1 (wtIDH1), enables the adaptation to these conditions. Under nutrient starvation, wtIDH1 oxidizes isocitrate to generate α-ketoglutarate (αKG) for anaplerosis, and NADPH to support antioxidant defense. In this study, we show that allosteric inhibitors of mutant IDH1 (mIDH1) are potent wtIDH1 inhibitors under conditions present in the TME. We demonstrate that low magnesium levels facilitate allosteric inhibition of wtIDH1, which is lethal to cancer cells when nutrients are limited. Furthermore, the FDA-approved mIDH1 inhibitor ivosidenib (AG-120) dramatically inhibited tumor growth in preclinical models of pancreatic cancer, highlighting this approach as a potential therapeutic strategy against wild-type IDH1 cancers.</p>

2022-04-29 | MTBLS4722 | MetaboLights

Coordinated single cell tumor microenvironment dynamics reinforce pancreatic cancer subtype

Project description:Coordinated single cell tumor microenvironment dynamics reinforce pancreatic cancer subtype

| PRJNA966248 | ENA

LY6D Identifies Persistent Tumor-Initiating Cells Driving Pancreatic Tumorigenesis [scRNA-seq]

Project description:LY6D Identifies Persistent Tumor-Initiating Cells Driving Pancreatic Tumorigenesis [scRNA-seq]

| PRJNA1274719 | ENA